Spyre Therapeutics completes SKYWAY Phase 2 rheumatoid arthritis sub-study enrollment, accelerates SPY072 Week 12 topline readout to Q3 2026
https://finviz.com/quote.ashx?t=SYRE&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.